PathomIQ

PathomIQ is pioneering an AI-driven, interpretable multiomics platform in the diagnostics sector, focusing on transforming precision oncology. Its core asset is a first-of-its-kind phenotype atlas trained on thousands of histopathology slides with corresponding genomic data, enabling the prediction of therapy response, metastasis risk, and gene mutations from routine tissue images. The company positions its solution as a faster, more cost-effective, and tissue-preserving alternative to standalone genomic assays, with demonstrated applications in prostate, triple-negative breast, and ER+/HER2- breast cancers. PathomIQ is a private, likely pre-revenue company seeking to establish its AI-powered predictive tests as a new standard in clinical decision support.

AI-powered interpretable multiomics platform that integrates digital pathology (morphology) with genomics. It uses a proprietary phenotype atlas trained on thousands of histopathology slides with genomic correlations to predict treatment response, outcomes, and gene mutations from standard H&E-stained tissue images.

PathomIQ competes in the rapidly evolving AI-digital pathology space against companies like Paige, PathAI, and Ibex Medical Analytics, as well as established genomic test providers (e.g., Exact Sciences, Myriad). Its key competitive claim is the unique integration of interpretable morphology with genomics to predict therapy response, positioning it as a potential complement or alternative to standalone genomic assays.